
For years, Pfizer has waged its internal battles, launching an array of new medicines with the hopes of rekindling growth. Yet, like many before them, these medicines, while clinically sound, have failed to bring forth the kind of profits their creators had envisaged. There is, however, a sense that the company has turned a corner, perhaps inadvertently, in its pursuit of the elusive next great pharmaceutical treasure. In a bold move, Pfizer has acquired Metsera, a biotech firm specializing in weight management therapies, for the substantial sum of $5 billion. The acquisition is a calculated gamble, one that could either lift the company from its current stagnation or plunge it deeper into uncertainty.